Prospects For Pfizer/Medivation's Dimebon Dashed By Phase III Flop
This article was originally published in The Pink Sheet Daily
The drug's inability to show an efficacy benefit highlights risks of Alzheimer's disease drug development and pressures Pfizer to pull off some pipeline wins.
You may also be interested in...
Surprise! It’s A Phase III Failure
When Phase III clinical trial failures happen it is a painful blow – to the drug manufacturer, to investors and to patients. Scrip takes a look at some of the biggest Phase III surprises since 2010.
Deals Of The Week: Genentech/Constellation, Bayer/Ventana, Genzyme/Veracyte
Epigenetics took the spotlight this week, with Genentech being the latest pharma to move into the field in partnership with Constellation Pharmaceuticals. In other deals, Bayer signed Ventana to develop a companion diagnostic, and Pfizer walked away from Medivation and Alzheimer’s drug Dimebon.
Pfizer/Medivation End Dimebon Development Following Another Failed Alzheimer’s Trial
A second failed efficacy trial, CONCERT, provided the final nail in the coffin for the once-promising treatment for Alzheimer’s disease, serving as a cautionary tale against excessive enthusiasm for early clinical trial results.